Literature DB >> 12563612

Allogeneic stem cell transplantation for chronic myeloid leukemia.

John Barrett1.   

Abstract

Allogeneic stem cell transplantation (SCT) plays a central role in chronic myeloid leukemia (CML) because it remains the only treatment with proven curative potential. For this reason, SCT has been more frequently performed in CML than in any other disease. The susceptibility of CML to the graft-versus-leukemia (GVL) effect and our ability to monitor minimal residual disease are particular features that place this disease at the forefront of GVL research. This review describes the mechanism of cure of CML by SCT, current results of transplantation, factors determining outcome, management of relapsed or persistent disease, and recent treatment advances.

Entities:  

Mesh：

Year:  2003        PMID： 12563612     DOI： 10.1053/shem.2003.50003

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  9 in total

1.  Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.

Authors:  Yi-Fen Lu; L Cristina Gavrilescu; Monica Betancur; Katherine Lazarides; Hans Klingemann; Richard A Van Etten
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.

Authors:  Vivian G Oehler; Ted Gooley; David S Snyder; Laura Johnston; Allen Lin; Carrie C Cummings; Su Chu; Ravi Bhatia; Stephen J Forman; Robert S Negrin; Frederick R Appelbaum; Jerald P Radich
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

3.  Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.

Authors:  Qaiser Bashir; Marcos J De Lima; John D McMannis; Guillermo Garcia-Manero; Elizabeth Shpall; Hagop Kantarjian; Jorge E Cortes; Susan M O'Brien; Dan Jones; Muzaffar Qazilbash; Wei Wei; Sergio A Giralt; Richard E Champlin; Chitra Hosing
Journal:  Leuk Lymphoma       Date:  2010-08

4.  Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.

Authors:  Jaspal Kaeda; Derville O'Shea; Richard M Szydlo; Eduardo Olavarria; Francesco Dazzi; David Marin; Susan Saunders; Jamshid S Khorashad; Nicholas C P Cross; John M Goldman; Jane F Apperley
Journal:  Blood       Date:  2006-01-31       Impact factor: 22.113

5.  Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.

Authors:  Nitin Jain; James M Reuben; Hagop Kantarjian; Changping Li; Hui Gao; Bang-Ning Lee; Evan N Cohen; Theresa Ebarb; David A Scheinberg; Jorge Cortes
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

6.  Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.

Authors:  A S M Yong; K Keyvanfar; R Eniafe; B N Savani; K Rezvani; E M Sloand; J M Goldman; A J Barrett
Journal:  Leukemia       Date:  2008-06-12       Impact factor: 11.528

7.  Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.

Authors:  Agnes S M Yong; Keyvan Keyvanfar; Nancy Hensel; Rhoda Eniafe; Bipin N Savani; Maria Berg; Andreas Lundqvist; Sharon Adams; Elaine M Sloand; John M Goldman; Richard Childs; A John Barrett
Journal:  Blood       Date:  2008-10-15       Impact factor: 22.113

8.  High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.

Authors:  Agnes S M Yong; Katayoun Rezvani; Bipin N Savani; Rhoda Eniafe; Stephan Mielke; John M Goldman; A John Barrett
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113

Review 9.  Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.

Authors:  Simona Soverini; Elisabetta Abruzzese; Monica Bocchia; Massimiliano Bonifacio; Sara Galimberti; Antonella Gozzini; Alessandra Iurlo; Luigiana Luciano; Patrizia Pregno; Gianantonio Rosti; Giuseppe Saglio; Fabio Stagno; Mario Tiribelli; Paolo Vigneri; Giovanni Barosi; Massimo Breccia
Journal:  J Hematol Oncol       Date:  2019-12-05       Impact factor: 17.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.